Protracted anti-obesity efficacy of lipidated PrRP31 analogues is most likely conferred by rapid in vivo conversion to corresponding peptide fragments with extended plasma stability and retained GPR10-NPFF2R agonist function. Here, PRLHR is linked to obesity disorder.